Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  fludeoxyglucose F 18
Find trials that include:  Any drugs shown
Results 1-25 of 66 for your search:
Start Over
18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients with Cancer Receiving Anti-Angiogenesis Therapy
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: VARIMG0002, NCI-2013-00535, NCT01806675
Multi-tracer PET/CT in Predicting and Assessing Response in Patients with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Receiving Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: HCI74163, NCI-2014-02370, 74163, NCI-2014-02286, NCT02245217
Fludeoxyglucose F 18-PET/CT Imaging in Assessing the Tumor and Planning Neck Surgery in Patients with Newly Diagnosed Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Health services research
Age: 18 and over
Trial IDs: ACRIN 6685, NCI-2011-01972, CA80098, CDR0000654703, NCT00983697
Response-Based Therapy Assessed by PET Scan in Treating Patients with Stage IA-IIB Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 to 60
Trial IDs: CALGB-50801, NCI-2011-02034, CDR0000669076, NCT01118026
Leuprolide Acetate in Improving Immune Recovery and 18F FLT PET/CT in Predicting Immune Recovery after Donor Bone Marrow Transplant in Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 9 to 55
Trial IDs: 11-C-0136, NCI-2013-01485, 110136, P10780, NCT01338987
PET-Directed Therapy in Treating Patients with Limited-Stage Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1001, NCI-2011-02673, CDR0000700624, SWOG-S1001, NCT01359592
Cabozantinib in Treating Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Involvement
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-208, NCI-2011-03519, XL184-IST12, NCT01441947
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients with Stage III Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG-1106, NCI-2012-00107, CDR0000721619, RTOG-1106/ACRIN-6697, NCT01507428
Gene and Vaccine Therapy in Treating Patients with Advanced Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: 12-000153, NCI-2012-01548, NCT01697527
FDG-PET in Predicting Treatment Response in Patients with Newly Diagnosed Stage II-IV Breast Cancer Receiving Pertuzumab and Trastuzumab Prior to Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 026, NCI-2014-01543, NA_00080994, NCI-2014-00245, NCT01937117
Total Marrow and Lymphoid Irradiation and Chemotherapy before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Lymphocytic or Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: 14012, NCI-2014-00639, 105023, 108097, 112566, NCT02094794
Nelfinavir Mesylate and Chemoradiotherapy in Treating Patients With Locally Advanced, Human Papilloma Virus Negative, Squamous Cell Carcinoma of the Larynx
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: UPCC 15313, NCI-2014-00591, NCT02207439
Fludeoxyglucose F-18 PET/MRI in Predicting Treatment Response in Patients with Newly Diagnosed Stage II or III Rectal Cancer Undergoing Chemoradiation Therapy
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: CC#144513, NCI-2015-00980, 133123, 144513, NCT02233595
FDG-PET Directed Treatment in Improving Response in Patients with Locally Advanced Stomach or Gastroesophageal Junction Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 18 and over
Trial IDs: A021302, NCI-2014-02566, NCT02485834
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients with Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: EA5123, NCI-2015-01054, NCT02607423
FLARE RT for Patients with Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9599, NCI-2016-00543, NCT02773238
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 09-051, NCI-2013-00407, NCT01360606
Sirolimus and Vismodegib in Treatment of Patients with Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MC1111, NCI-2011-03809, NCT01537107
Ipilimumab or Nivolumab in Treating Patients with Relapsed Hematologic Malignancies after Donor Stem Cell Transplant
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9204, NCI-2013-00739, 12-537, NCT01822509
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients with Locally Advanced or Metastatic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 16 and over
Trial IDs: 13-001624, NCI-2014-00221, 1311-1278, 208.13.0-h, CA184-346, NCT02070406
18F-FDG PET/CT before Surgery in Mapping Lymph Nodes in Patients with Stage IB Cervical Cancer or High-Grade Endometrial Cancer
Status: Active
Phase: Phase I
Type: Diagnostic
Age: 18 to 75
Trial IDs: 14-222, NCI-2014-02552, NCT02285192
18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: 2014-0616, NCI-2015-00525, NCT02390635
Sapanisertib and Alisertib in Treating Patients with Incurable Refractory Solid Tumors or Metastatic Triple-Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 15-1135, NCI-2016-00443, NCT02719691
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients with Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 16 and over
Trial IDs: 15-001433, NCI-2016-00201, NCT02775292
18F-FDG PET or 1H-MRSI in Assessing Tumor Activity in Younger Patients with Brain Tumors
Status: Active
Phase: No phase specified
Type: Diagnostic, Natural history/Epidemiology
Age: 1 to 21
Trial IDs: 03-C-0278, NCI-2013-02042, 030278, NCT00070512, NCI-03-C-0278, NCT00067821
Start Over